Search | Clinical Trials Finder

Conditions: Epithelial Ovarian Cancer
Interventions: Cvac, Placebo; Biological
Lead sponsor: Prima BioMed Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more

Conditions: Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions: Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metastatic Colorectal Cancer
Interventions: Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
Interventions: Consolidative radiation therapy (cRT); Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 39 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota

Conditions: B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions: carfilzomib, Cytokine Assessment, Pharmacodynamic Studies, Proteosome Inhibition Assessment, Pharmacogenomic Studies; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions: Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cleft Palates
Interventions: Unasyn, saline solution; Drug · Other
Lead sponsor: Joseph Losee; Other
Eligibility: 3 Months to 18 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
Interventions: PCA plus methadone (Experimental), PCA Alone (SOC); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Interventions: certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo; Drug
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 19
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Non-small Cell Lung Cancer
Interventions: SBRT, First or second-line standard of care therapy; Radiation · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 71
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 55 more

Conditions: Advanced Solid Tumors
Interventions: M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen; Drug · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Interventions: IDRX-42; Drug
Lead sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Interventions: silevertinib (BDTX-1535) monotherapy; Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more

Conditions: Cancer
Interventions: GA-driven Intervention; Other
Lead sponsor: University of Rochester; Other
Eligibility: 70 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Rochester, New York

Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Interventions: Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Skin Scarring, Skin Elasticity
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pleural Mesothelioma, Non-small Cell Lung Cancer
Interventions: THOR-707, Pembrolizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Deep Venous Thrombosis
Interventions: Thrombolysis/Thrombectomy; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more

Conditions: Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab; Drug · Biological · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Goodyear, Arizona • Corona, California • Duarte, California + 10 more

Conditions: Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping; Drug · Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
Interventions: Obrixtamig, Pumitamig, Carboplatin, Etoposide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • East Brunswick, New Jersey + 2 more

Conditions: Adenocarcinoma
Interventions: Trastuzumab, ABT-806, Bemarituzumab, Ramucirumab, Nivolumab, Standard cytotherapy; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Preventing Complications in Cleft Palate Repair With Antibiotics

Methadone as an Alternative Treatment for Children Underdoing HSCT

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Skin Elasticity Measurements of the Face and Surgical Scars Stratified by Age and Skin Type

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Second Line Endovascular Treatment in Acute DVT

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer